MAP2K7 and intrahepatic cholangiocarcinoma: Through a cohort study, the Zhou SL team evaluated broad differences among organoids with different BRAF variant subtypes in sensitivity to BRAF or MEK inhibitors, and suggested a precise treatment for patients with intrahepatic cholangiocarcinoma (ICC) (Xin et al., 2023).